Does Immunohistochemistry Provide Additional Prognostic Data in Gastrointestinal Stromal Tumors?

被引:12
作者
Demir, Lutfiye [1 ]
Ekinci, Nese [2 ]
Erten, Cigdem [1 ]
Kucukzeybek, Yuksel [1 ]
Alacacioglu, Ahmet [1 ]
Somali, Isil [3 ]
Can, Alper [1 ]
Dirican, Ahmet [1 ]
Bayoglu, Vedat [1 ]
Akyol, Murat [1 ]
Cakalagaoglu, Fulya [2 ]
Tarhan, Mustafa Oktay [1 ]
机构
[1] Izmir Katip Celebi Univ, Ataturk Training & Res Hosp, Dept Med Oncol, Izmir, Turkey
[2] Izmir Katip Celebi Univ, Ataturk Training & Res Hosp, Dept Pathol, Izmir, Turkey
[3] Dokuz Eylul Univ, Inst Oncol, Dept Med Oncol, TR-35210 Alsancak, Turkey
关键词
Gastrointestinal stromal tumor; immunohistochemistry; predictive potential; prognosis; IMATINIB MESYLATE; C-KIT; GIST; MUTATIONS; SURVIVAL; RECURRENCE; RESISTANCE; DIAGNOSIS;
D O I
10.7314/APJCP.2013.14.8.4751
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: To investigate the predictive and prognostic effects of clinicopathologic and immunohistochemical (IHC) features in patients with gastrointestinal stromal tumours (GISTs). Materials and Methods: Fifty-six patients who were diagnosed with GIST between 2002 and 2012 were retrospectively evaluated. Relationships between clinicopathologic/immunohistochemical factors and prognosis were investigated. Results: Median overall survival (OS) of the whole study group was 74.9 months (42.8-107.1 months), while it was 95.2 months in resectable and 44.7 months in metastatic patients respectively (p=0.007). Epitheliolid tumor morphology was significantly associated with shortened OS as compared to other histologies (p=0.001). SMA(+) tumours were significantly correlated with low (<10/50HPF) mitotic activity (p=0.034). Moreover, SMA(+) patients tended to survive longer and had significantly longer disease-free survival (DFS) times than SMA (-) patients (37.7 months vs 15.9 months; p=0.002). High Ki-67 level (>= 30%) was significantly associated with shorter OS (34 vs 95.2 months; 95% CI; p=0.001). CD34 (-) tumours were significantly associated with low proliferative tumours (Ki-67<% 10) (p=0.026). Median PFS (progression-free survival) of the patients who received imatinib was 36 months (27.7-44.2 months). CD34 (-) patients had significantly longer PFS times than that of negative tumours; (50.8 vs 29.8 months; p=0.045). S100 and desmin expression did not play any role in predicting the prognosis of GISTs. Multivariate analysis demonstrated that >= 10/50HPF mitotic activity/HPF was the only independent factor for risk of death in GIST patients. Conclusions: Despite the negative prognostic and predictive effect of high Ki-67 and CD34 expression, mitotic activity remains the strongest prognostic factor in GIST patients. SMA positivity seems to affect GIST prognosis positively. However, large-scale, multicenter studies are required to provide supportive data for these findings.
引用
收藏
页码:4751 / 4758
页数:8
相关论文
共 44 条
[11]   Clonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumors [J].
Desai, Jayesh ;
Shankar, Sridhar ;
Heinrich, Michael C. ;
Fletcher, Jonathan A. ;
Fletcher, Christopher D. ;
Manola, Judi ;
Morgan, JeffreyA. ;
Corless, Christopher L. ;
George, Suzanne ;
Tuncali, Kemal ;
Silverman, Stuart G. ;
Van den Abbeele, Annick D. ;
van Sonnenberg, Eric ;
Demetri, George D. .
CLINICAL CANCER RESEARCH, 2007, 13 (18) :5398-5405
[12]   New response evaluation criteria in solid tumours: Revised RECIST guideline (version 1.1) [J].
Eisenhauer, E. A. ;
Therasse, P. ;
Bogaerts, J. ;
Schwartz, L. H. ;
Sargent, D. ;
Ford, R. ;
Dancey, J. ;
Arbuck, S. ;
Gwyther, S. ;
Mooney, M. ;
Rubinstein, L. ;
Shankar, L. ;
Dodd, L. ;
Kaplan, R. ;
Lacombe, D. ;
Verweij, J. .
EUROPEAN JOURNAL OF CANCER, 2009, 45 (02) :228-247
[13]   Diagnosis of gastrointestinal stromal tumors: A consensus approach [J].
Fletcher, CDM ;
Berman, JJ ;
Corless, C ;
Gorstein, F ;
Lasota, J ;
Longley, BJ ;
Miettinen, M ;
O'Leary, TJ ;
Remotti, H ;
Rubin, BP ;
Shmookler, B ;
Sobin, LH ;
Weiss, SW .
HUMAN PATHOLOGY, 2002, 33 (05) :459-465
[14]   Clinicopathologic study of primary malignant gastrointestinal stromal tumor of the stomach, with special reference to prognostic factors: Analysis of results in 140 surgically resected patients [J].
Yoshiya Fujimoto ;
Yukihiro Nakanishi ;
Kimio Yoshimura ;
Tadakazu Shimoda .
Gastric Cancer, 2003, 6 (1) :39-48
[15]   Molecular correlates of imatinib resistance in gastrointestinal stromal tumors [J].
Heinrich, Michael C. ;
Corless, Christopher L. ;
Blanke, Charles D. ;
Demetri, George D. ;
Joensuu, Heikki ;
Roberts, Peter J. ;
Eisenberg, Burton L. ;
von Mehren, Margaret ;
Fletcher, Christopher D. M. ;
Sandau, Katrin ;
McDougall, Karen ;
Ou, Wen-bin ;
Chen, Chang-Jie ;
Fletcher, Jonathan A. .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (29) :4764-4774
[16]   Sorafenib Inhibits Many Kinase Mutations Associated with Drug-Resistant Gastrointestinal Stromal Tumors [J].
Heinrich, Michael C. ;
Marino-Enriquez, Adrian ;
Presnell, Ajia ;
Donsky, Rachel S. ;
Griffith, Diana J. ;
McKinley, Arin ;
Patterson, Janice ;
Taguchi, Takahiro ;
Liang, Cher-Wei ;
Fletcher, Jonathan A. .
MOLECULAR CANCER THERAPEUTICS, 2012, 11 (08) :1770-1780
[17]   Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors [J].
Hirota, S ;
Isozaki, K ;
Moriyama, Y ;
Hashimoto, K ;
Nishida, T ;
Ishiguro, S ;
Kawano, K ;
Hanada, M ;
Kurata, A ;
Takeda, M ;
Tunio, GM ;
Matsuzawa, Y ;
Kanakura, Y ;
Shinomura, Y ;
Kitamura, Y .
SCIENCE, 1998, 279 (5350) :577-580
[18]   The rote of KIT in the management of patients with gastrointestinal stromal tumors [J].
Hornick, Jason L. ;
Fletcher, Christopher D. M. .
HUMAN PATHOLOGY, 2007, 38 (05) :679-687
[19]  
Hornick JL, 2002, AM J CLIN PATHOL, V117, P188
[20]   Risk stratification of patients diagnosed with gastrointestinal stromal tumor [J].
Joensuu, Heikki .
HUMAN PATHOLOGY, 2008, 39 (10) :1411-1419